Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 3

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 3
---
 to trademarks,
trade names and service marks belonging to other entities. Solely for convenience, trademarks, trade names and service marks referred
to in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference into this prospectus supplement
and the accompanying prospectus may appear without the ® or TM symbols, but such references are not intended to indicate, in any way,
that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names.
We do not intend our use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or
endorsement or sponsorship of us by, any other companies.

Except where the context otherwise requires or
where otherwise indicated in this prospectus supplement, the terms “Alpha Tau,” the “Company,” “we,”
“us,” “our,” “our company” and “our business” refer to Alpha Tau Medical Ltd., together
with its consolidated subsidiaries as a consolidated entity. The term “ordinary shares” refers to our ordinary shares, no
par value per share. The term “existing warrants” refers to our 15,747,561 outstanding warrants to purchase ordinary shares
(as of December 31, 2024), each entitling its holder to purchase one ordinary share at an exercise price equal to $11.50.

<div align='center'>S-ii

PROSPECTUS SUPPLEMENT SUMMARY</div>

The following summary of our business highlights certain of the information contained elsewhere in, or incorporated by reference into, this prospectus supplement and the accompanying base prospectus. This summary does not contain all of the information that may be important to you. You should carefully read this entire prospectus supplement and the accompanying base prospectus, including any information incorporated by reference, which are described under the headings “Where You Can Find More Information; Incorporation of Information by Reference” herein and therein. In particular, you should carefully consider the risks and uncertainties described under the heading “Risk Factors” in this prospectus supplement and in the accompanying base prospectus, as well as those contained in the other documents incorporated by reference and any related free writing prospectus. As used in this prospectus supplement, unless the context otherwise requires, references to “we,” “us,” “our,” “our company” and “Alpha Tau,” refer to Alpha Tau Medical Ltd.

Overview

We are a clinical-stage oncology therapeutics
company focused on harnessing the innate relative biological effectiveness and short